References
- Sandborn WJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol 1998; 33 Suppl 225: 92–9.
- Schölmerich J. Immunosuppresive therapy for chronic inflammatory bowel disease. Digestion 1997; 58 Suppl 1: 94–7.
- Rutgeerts P. Medical therapy of inflammatory bowel disease. Digestion 1998; 59: 453–69.
- Marion JF, Present DH. The modern medical management of acute, severe ulcerative colitis. Eur J Gastroenterol Hepatol 1997; 9: 831–5.
- Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercapto-purine: a long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981–7.
- Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med 1995; 123: 132–42.
- Rhodes J, Bainton D, Beck P, Cambell H. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971; 2: 1273–6.
- Klein M, Binder HJ, Mitchell M, Aaronson R, Spiro H. Treatment of Crohn’s disease with azathioprine: a controlled evaluation. Gastroenterology 1974; 66: 916–22.
- Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995; 37: 674–8.
- Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F, Jr et al. National cooperative Crohn’s disease study: results of drug treatment. Gastroenterology 1979; 77: 847–69.
- Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 1993; 105: 367–72.
- Willoughby JMT, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn’s disease. Lancet 1971; 2: 944–7.
- Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn’s disease. Am J Dig Dis 1975; 20: 721–6.
- O’Donoghue DP, Dawson AM, Powell-Tuck J, Brown RL, Lennard-Jones J. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn’s disease. Lancet 1978; 2: 955–7.
- Bouhnik Y, Lemann M, Mary JY, Scemama G, Taï R, Matuchansky C, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215–9.
- D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn’s disease. Gastroenterology 1997; 112: 1475–81.
- Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641–9.
- Krischner DS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813–21.
- Lavaud F, Abdelli N, Thiefin G. Successful desensitization for azathioprine skin rash in a patient with severe Crohn’s disease. Dig Dis Sci 1997; 42: 823.
- Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081–5.
- Postuma EFM, Westendorp RGJ, Sluys Veer van der, Kluin-Nelemans JC, Kluin PhM, Lamers CBHW. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn’s disease with azathioprine. Gut 1995; 36: 311–3.
- Modigliani R. Drug therapy for ulcerative colitis during pregnancy. Eur J Gastroenterol Hepatol. 1997; 9: 854–7.
- Subhani JM, Hamilton MI. The management of inflammatory bowel disease during pregnancy. Alliment Pharmacol Ther 1998; 12: 1039–53.
- Cuffari C, Sharma S. 6-Mercaptopurine metabolite levels tailored to achieve clinical responsiveness in pediatric Crohn’s disease. Gastroenterology 1999; 116: A694.
- Cuffari C, Picco M, Hunt S, Bayless T. Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD. Gastroenterology 1999; 116: A694.
- Colombel JF, Touze I, Catala P, et al. Genotypic analysis of the thiopurine S-Methyltransferase (TPMT) gene in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 1999; 116: A688.
- Hassan C, Duley J, Ansari A, et al. Thiopurine S-methyltrans-ferase activity in inflammatory bowel disease: a retrospective study. Gastroenterology 1999; 1l6: A733.
- Sandborn WJ, Van Os EC, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn’s disease. Gastroenterology 1995; 109: 1808–17.